BioCardia, Inc. (NASDAQ:BCDA) Short Interest Down 12.6% in September

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a large decrease in short interest in the month of September. As of September 30th, there was short interest totalling 132,100 shares, a decrease of 12.6% from the September 15th total of 151,200 shares. Currently, 4.8% of the company’s stock are short sold. Based on an average daily volume of 832,300 shares, the short-interest ratio is currently 0.2 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright boosted their price objective on BioCardia from $4.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, August 16th.

BioCardia Stock Down 5.8 %

Shares of NASDAQ:BCDA opened at $2.44 on Wednesday. The company has a 50 day moving average of $2.78 and a two-hundred day moving average of $3.83. BioCardia has a 52-week low of $1.96 and a 52-week high of $23.25. The company has a market capitalization of $4.44 million, a price-to-earnings ratio of -0.35 and a beta of 1.26.

BioCardia (NASDAQ:BCDA) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.78). On average, equities analysts anticipate that BioCardia will post -5.06 earnings per share for the current year.

About BioCardia

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.